vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and Silvercrest Asset Management Group Inc. (SAMG). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $32.0M, roughly 1.1× Silvercrest Asset Management Group Inc.). Silvercrest Asset Management Group Inc. runs the higher net margin — -0.4% vs -299.9%, a 299.5% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -0.0%). Over the past eight quarters, Silvercrest Asset Management Group Inc.'s revenue compounded faster (2.7% CAGR vs 1.4%).
KPTI vs SAMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $32.0M |
| Net Profit | $-102.2M | $-120.0K |
| Gross Margin | — | — |
| Operating Margin | -52.4% | -2.8% |
| Net Margin | -299.9% | -0.4% |
| Revenue YoY | 11.6% | -0.0% |
| Net Profit YoY | -232.0% | -107.4% |
| EPS (diluted) | $-7.02 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $32.0M | ||
| Q3 25 | $44.0M | $31.3M | ||
| Q2 25 | $37.9M | $30.7M | ||
| Q1 25 | $30.0M | $31.4M | ||
| Q4 24 | $30.5M | $32.0M | ||
| Q3 24 | $38.8M | $30.4M | ||
| Q2 24 | $42.8M | $31.0M | ||
| Q1 24 | $33.1M | $30.3M |
| Q4 25 | $-102.2M | $-120.0K | ||
| Q3 25 | $-33.1M | $618.0K | ||
| Q2 25 | $-37.3M | $1.9M | ||
| Q1 25 | $-23.5M | $2.5M | ||
| Q4 24 | $-30.8M | $1.6M | ||
| Q3 24 | $-32.1M | $2.3M | ||
| Q2 24 | $23.8M | $2.7M | ||
| Q1 24 | $-37.4M | $3.0M |
| Q4 25 | -52.4% | -2.8% | ||
| Q3 25 | -34.6% | 4.3% | ||
| Q2 25 | -64.3% | 13.2% | ||
| Q1 25 | -110.8% | 15.4% | ||
| Q4 24 | -102.4% | 6.1% | ||
| Q3 24 | -67.8% | 14.6% | ||
| Q2 24 | -65.7% | 17.1% | ||
| Q1 24 | -101.9% | 19.5% |
| Q4 25 | -299.9% | -0.4% | ||
| Q3 25 | -75.2% | 2.0% | ||
| Q2 25 | -98.2% | 6.3% | ||
| Q1 25 | -78.2% | 7.9% | ||
| Q4 24 | -100.8% | 5.1% | ||
| Q3 24 | -82.7% | 7.4% | ||
| Q2 24 | 55.6% | 8.6% | ||
| Q1 24 | -112.8% | 9.9% |
| Q4 25 | $-7.02 | $0.02 | ||
| Q3 25 | $-3.82 | $0.07 | ||
| Q2 25 | $-4.32 | $0.21 | ||
| Q1 25 | $-2.77 | $0.26 | ||
| Q4 24 | $-2.33 | $0.16 | ||
| Q3 24 | $-3.85 | $0.24 | ||
| Q2 24 | $-2.97 | $0.28 | ||
| Q1 24 | $-4.85 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $44.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $50.3M |
| Total Assets | $108.4M | $166.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $44.1M | ||
| Q3 25 | $37.7M | $36.1M | ||
| Q2 25 | $38.7M | $30.0M | ||
| Q1 25 | $38.8M | $36.3M | ||
| Q4 24 | $62.5M | $68.6M | ||
| Q3 24 | $72.8M | $58.1M | ||
| Q2 24 | $84.8M | $49.9M | ||
| Q1 24 | $30.6M | $39.7M |
| Q4 25 | $-292.9M | $50.3M | ||
| Q3 25 | $-269.3M | $58.9M | ||
| Q2 25 | $-238.9M | $64.6M | ||
| Q1 25 | $-205.9M | $80.0M | ||
| Q4 24 | $-186.0M | $80.7M | ||
| Q3 24 | $-159.6M | $84.6M | ||
| Q2 24 | $-132.1M | $85.3M | ||
| Q1 24 | $-169.0M | $83.9M |
| Q4 25 | $108.4M | $166.6M | ||
| Q3 25 | $96.2M | $157.6M | ||
| Q2 25 | $104.9M | $152.7M | ||
| Q1 25 | $127.7M | $159.9M | ||
| Q4 24 | $164.4M | $194.4M | ||
| Q3 24 | $189.5M | $184.2M | ||
| Q2 24 | $214.0M | $177.6M | ||
| Q1 24 | $204.5M | $170.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $18.6M |
| Free Cash FlowOCF − Capex | — | $15.0M |
| FCF MarginFCF / Revenue | — | 46.9% |
| Capex IntensityCapex / Revenue | 0.0% | 11.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $17.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $18.6M | ||
| Q3 25 | $-5.9M | $14.6M | ||
| Q2 25 | $-18.7M | $13.8M | ||
| Q1 25 | $-39.0M | $-24.7M | ||
| Q4 24 | $-25.8M | $21.6M | ||
| Q3 24 | $-19.5M | $13.3M | ||
| Q2 24 | $-38.5M | $16.0M | ||
| Q1 24 | $-43.7M | $-24.1M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $13.4M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | $-25.9M | $19.9M | ||
| Q3 24 | — | $12.9M | ||
| Q2 24 | — | $15.6M | ||
| Q1 24 | $-43.9M | $-24.7M |
| Q4 25 | — | 46.9% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | -80.0% | ||
| Q4 24 | -84.7% | 62.2% | ||
| Q3 24 | — | 42.4% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | -132.6% | -81.6% |
| Q4 25 | 0.0% | 11.4% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | 0.2% | 5.3% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | 0.6% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | — | -10.01× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 5.90× | ||
| Q2 24 | -1.62× | 6.00× | ||
| Q1 24 | — | -8.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
